Core Insights - LifeMD Inc is a significant player in the virtual healthcare industry, recognized for its innovative telehealth platform and strong revenue growth, earning spots on the 2025 Deloitte Technology Fast 500 and TIME's America's Growth Leaders of 2026 lists [1][5] Financial Performance - On November 24, 2025, Loop Capital Markets set a price target of $8 for LFMD, indicating a potential price increase of about 98.49% from its trading price of $3.97, reflecting the company's robust market position [2][5] - LifeMD's stock has shown volatility, with a recent price range between $3.91 and $4.06, and a 3.12% increase over a recent period, with a change of $0.12 [3] - Over the past year, LFMD's stock has fluctuated significantly, reaching a high of $15.84 and a low of $3.43, indicating substantial growth potential [3][5] Market Position and Strategy - The company's market capitalization is approximately $191.1 million, with a trading volume of 1,106,676 shares, positioning it well for future success [4] - LifeMD is focusing on expanding its offerings in high-growth markets such as weight management and mental health, which supports the positive price target set by Loop Capital Markets [4]

Financial Performance - Q3 2025 - Revenue for 3Q-25 was $626 million, a decrease of 2% year-over-year[4] - Net loss per share for 3Q-25 was $(0.28)[4] - Adjusted EBITDA for 3Q-25 was $69.9 million, a decrease of 16% year-over-year[4] Financial Outlook - FY25 - The company projects FY-25 revenue to be in the range of $2,510 million to $2,539 million[5] - The company projects FY-25 net loss per share to be in the range of $(1.25) to $(1.10)[5] - The company projects FY-25 Adjusted EBITDA to be in the range of $270 million to $287 million[5] Financial Outlook - Q4 2025 - The company projects 4Q-25 revenue to be in the range of $622 million to $652 million[5] - The company projects 4Q-25 net loss per share to be in the range of $(0.25) to $(0.10)[5] - The company projects 4Q-25 Adjusted EBITDA to be in the range of $73 million to $90 million[5] Balance Sheet and Cash Flow - Cash and cash equivalents as of September 30, 2025, were $726 million[36] - Convertible senior notes as of September 30, 2025, were $994 million[36] - Operating cash flow for 3Q-25 was $99 million[36] - Free cash flow for 3Q-25 was $68 million[36]